[go: up one dir, main page]

WO2008033987A3 - Compositions et procédés de prévention du cancer avec des cupredoxines - Google Patents

Compositions et procédés de prévention du cancer avec des cupredoxines Download PDF

Info

Publication number
WO2008033987A3
WO2008033987A3 PCT/US2007/078371 US2007078371W WO2008033987A3 WO 2008033987 A3 WO2008033987 A3 WO 2008033987A3 US 2007078371 W US2007078371 W US 2007078371W WO 2008033987 A3 WO2008033987 A3 WO 2008033987A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
cupredoxins
tissues
animals
development
Prior art date
Application number
PCT/US2007/078371
Other languages
English (en)
Other versions
WO2008033987A2 (fr
Inventor
Gupta Tapas Das
Ananda Chakrabarty
Original Assignee
Univ Illinois
Gupta Tapas Das
Ananda Chakrabarty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Gupta Tapas Das, Ananda Chakrabarty filed Critical Univ Illinois
Priority to MX2009002787A priority Critical patent/MX2009002787A/es
Priority to CA002663498A priority patent/CA2663498A1/fr
Priority to BRPI0714987-5A priority patent/BRPI0714987A2/pt
Priority to JP2009528468A priority patent/JP2010503409A/ja
Priority to EP07842403A priority patent/EP2061498A4/fr
Priority to AU2007296429A priority patent/AU2007296429A1/en
Publication of WO2008033987A2 publication Critical patent/WO2008033987A2/fr
Priority to IL197602A priority patent/IL197602A0/en
Priority to NO20091267A priority patent/NO20091267L/no
Publication of WO2008033987A3 publication Critical patent/WO2008033987A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions constituées de peptides pouvant être des variantes, des dérivés et des équivalents structurels des cupredoxines qui inhibent le développement de lésions prémalignes dans des cellules, des tissus et des animaux mammaliens. De manière spécifique, ces compositions peuvent contenir de l'azurine de Pseudomonas aeruginosa, et/ou la région résiduelle 50-77 de l'azurine (p28). La présente invention concerne en outre des compositions qui peuvent contenir une ou plusieurs cupredoxines, et/ou des variantes, des dérivés ou des équivalents structurels des cupredoxines et peuvent conserver la capacité d'inhiber le développement de lésions prémalignes dans des cellules, des tissus ou des animaux mammaliens. Ces compositions peuvent, entre autres, être des peptides ou des compositions pharmaceutiques. Il est possible d'utiliser les compositions de l'invention pour prévenir le développement de lésions prémalignes dans des cellules, des tissus et des animaux mammaliens, et de ce fait prévenir le cancer.
PCT/US2007/078371 2006-09-14 2007-09-13 Compositions et procédés de prévention du cancer avec des cupredoxines WO2008033987A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MX2009002787A MX2009002787A (es) 2006-09-14 2007-09-13 Composiciones y métodos para prevenir el cáncer con cupredoxinas.
CA002663498A CA2663498A1 (fr) 2006-09-14 2007-09-13 Compositions et procedes de prevention du cancer avec des cupredoxines
BRPI0714987-5A BRPI0714987A2 (pt) 2006-09-14 2007-09-13 composiÇÕes e mÉtodos para a prevenÇço do cÂncer com cupredoxina
JP2009528468A JP2010503409A (ja) 2006-09-14 2007-09-13 クプレドキシンによって癌を予防する組成物および方法
EP07842403A EP2061498A4 (fr) 2006-09-14 2007-09-13 Compositions et procédés de prévention du cancer avec des cupredoxines
AU2007296429A AU2007296429A1 (en) 2006-09-14 2007-09-13 Compositions and methods to prevent cancer with cupredoxins
IL197602A IL197602A0 (en) 2006-09-14 2009-03-15 Compositions and methods to prevent cancer with cupredoxins
NO20091267A NO20091267L (no) 2006-09-14 2009-03-26 Sammensetninger og fremgangsmåter for å forebygge kreft med cupredoxiner

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84435806P 2006-09-14 2006-09-14
US60/844,358 2006-09-14

Publications (2)

Publication Number Publication Date
WO2008033987A2 WO2008033987A2 (fr) 2008-03-20
WO2008033987A3 true WO2008033987A3 (fr) 2009-04-30

Family

ID=39184582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078371 WO2008033987A2 (fr) 2006-09-14 2007-09-13 Compositions et procédés de prévention du cancer avec des cupredoxines

Country Status (13)

Country Link
EP (1) EP2061498A4 (fr)
JP (2) JP2010503409A (fr)
KR (1) KR20090059152A (fr)
CN (1) CN101595124A (fr)
AU (1) AU2007296429A1 (fr)
BR (1) BRPI0714987A2 (fr)
CA (1) CA2663498A1 (fr)
IL (1) IL197602A0 (fr)
MX (1) MX2009002787A (fr)
NO (1) NO20091267L (fr)
RU (1) RU2009113812A (fr)
SG (1) SG174784A1 (fr)
WO (1) WO2008033987A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
US9598470B2 (en) * 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
AU2005327535A1 (en) 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
EP1904642A4 (fr) 2005-07-19 2008-11-26 Univ Illinois Agents de transport utiles pour traverser la barriere hemato-encephalique et pour penetrer dans les cellules cancereuses du cerveau, methodes d'utilisation de ces derniers
MX2009005849A (es) 2006-12-04 2009-08-12 Univ Illinois Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
CN101668536A (zh) 2007-02-08 2010-03-10 伊利诺斯大学理事会 用铜氧还蛋白预防癌症的组合物和方法
US12331360B2 (en) 2017-09-29 2025-06-17 Oncgnostics Gmbh Risk determination for neoplasia and cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
CN1506375A (zh) * 2002-12-12 2004-06-23 浙江养生堂天然药物研究所有限公司 具有广谱抗肿瘤作用的细菌蛋白天青蛋白及其用途和含有其的药物组合物
AU2005327535A1 (en) * 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
AU2006277009A1 (en) * 2005-05-20 2007-02-15 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
KR20080034905A (ko) * 2005-07-19 2008-04-22 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신으로 혈관신생을 제어하는 조성물과 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARVIDSSON ET AL.: "The azurin gene from Pseudomonas aeruginosa cloning and characterization.", EUR. J. BIOCHEM., vol. 179, 1989, pages 195 - 200, XP008107831 *
YAMADA ET AL.: "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer.", PNAS, vol. 99, no. 22, 2002, pages 14098 - 14103, XP002486971 *

Also Published As

Publication number Publication date
IL197602A0 (en) 2011-08-01
MX2009002787A (es) 2009-08-27
JP2010503409A (ja) 2010-02-04
KR20090059152A (ko) 2009-06-10
WO2008033987A2 (fr) 2008-03-20
JP2014050390A (ja) 2014-03-20
AU2007296429A1 (en) 2008-03-20
SG174784A1 (en) 2011-10-28
NO20091267L (no) 2009-06-04
CN101595124A (zh) 2009-12-02
RU2009113812A (ru) 2010-10-20
EP2061498A2 (fr) 2009-05-27
CA2663498A1 (fr) 2008-03-20
EP2061498A4 (fr) 2009-11-04
BRPI0714987A2 (pt) 2013-07-30

Similar Documents

Publication Publication Date Title
WO2008033987A3 (fr) Compositions et procédés de prévention du cancer avec des cupredoxines
WO2007044084A3 (fr) Inhibiteurs heterocycliques de mek et leurs procedes d'utilisation
WO2009109927A3 (fr) Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
WO2009038689A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2008030273A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2007077561A3 (fr) Compositions et procédés permettant d'améliorer le captage in-vivo d'agents pharmaceutiques
WO2006108075A3 (fr) Compositions et methodes accroissant la sensibilite aux medicaments et traitant les infections et maladies presentant une resistance aux medicaments
WO2006133271A3 (fr) Compositions et methodes portant sur une therapie photodynamique ciblee
WO2007056681A3 (fr) Procedes d'administration d'agents hypoglycemiques
WO2008133722A3 (fr) Anticorps et diagnostics
MX358617B (es) Formulaciones de inhibidores de dpp iv.
WO2007102149A3 (fr) Dérivés hydrazido de l'acide hyaluronique
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2011008495A3 (fr) Formulations d'arginase et procédés
CL2011000867A1 (es) Formas cristalinas da, c y ii de (r)-5-[3-cloro-4-(2,3-dihidroxi-propoxi)- benz[z]ilideno]-2- ([z]- propilimino) -3-o- totil-tiazolidin-4-ona; composicion farmaceutica; y uso en el tratamiento o prevencion de rechazo de organos trasplantados, sindrome autoinmunitarios, asma, diabetes, cancer.
WO2008030412A3 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d'alzheimer
WO2007061939A3 (fr) Dérivés de métabolites de l'inhibiteur de hdac fk228
WO2008117125A3 (fr) Compositions capables de faciliter la pénétration à travers une barrière biologique
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2009016181A3 (fr) Agents pour l'imagerie optique
WO2008054698A3 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
WO2007067519A3 (fr) Utilisation de neurotransmetteurs et de neuropeptides pour le traitement de maladies de secheresse oculaire et de conditions associees
WO2007058862A3 (fr) Composes d’imidazolidinone utiles en tant qu’inhibiteurs de la beta-secretase lors du traitement de la maladie d’alzheimer
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
WO2008132021A3 (fr) Mélanges fongicides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780041762.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842403

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 575506

Country of ref document: NZ

Ref document number: 2007296429

Country of ref document: AU

Ref document number: 2663498

Country of ref document: CA

Ref document number: 521/MUMNP/2009

Country of ref document: IN

Ref document number: MX/A/2009/002787

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2009528468

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007842403

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007296429

Country of ref document: AU

Date of ref document: 20070913

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097007352

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009113812

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0714987

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090313